Evaluation and Application of Donors with Primary Central Nervous System Tumors

TitleEvaluation and Application of Donors with Primary Central Nervous System Tumors
Publication TypeJournal Article
Year of Publication2019
AuthorsWu JH, Qiao PF, Sun XY, Dong JH, Liao JX, Liu XY, Gao Z, Lan LG, Li HB, Su QD
Date PublishedOct

Background: This study aimed to explore the safety of donors with primary central nervous system tumors for kidney and liver transplantations.

Methodology: Clinical data of 29 donors with primary CNS tumors in January 2007 to December 2017, as well as the follow-up data of 16 liver transplant recipients and 46 kidney transplant recipients, were analyzed. According to the risk factors, the high-risk group was classified as Group 1, the low-risk factors were classified as Group 2, and the unknown risk group was classified as Group 3. The incidence of donor-transmitted CNS tumors was calculated and compared.

Results: The duration from the diagnosis of 29 donors to donation was 5.67 ± 6.36 months. None of the liver and kidney transplant recipients who were followed up had tumor metastasis. Although the mean survival time of Group 1 was lower than that of Group 2 and Group 3, the Kaplan-Meier curve showed no significant difference in survival time.

Conclusion: No obvious difference was observed between high-risk and low-risk and unknown risk CNS tumors in terms of the survival rate of transplants and tumor metastasis rate. High-risk CNS tumor donors can be used with the informed consent of recipients after a full evaluation.

Alternate JournalClin Transplant.
Notify Library Reference ID4892